Identification of royal jelly as a potential new drug to protect the ovarian reserve and uterus against cyclophosphamide in rats

Basit Öğe Kaydı
dc.authoridTEKCE, ALI/0000-0002-1626-6626
dc.authoridKorkmaz, Omer/0000-0001-5179-2181
dc.authoridBULBUL, Mehmet/0000-0001-5695-2586
dc.contributor.authorBulbul, Mehmet
dc.contributor.authorTekce, Ali
dc.contributor.authorAnnac, Ebru
dc.contributor.authorKorkmaz, Omer
dc.contributor.authorOnderci, Muhittin
dc.contributor.authorKorkmaz, Deniz
dc.contributor.authorDemirci, Akin Mustafa
dc.date.accessioned2024-09-29T16:09:57Z
dc.date.available2024-09-29T16:09:57Z
dc.date.issued2023
dc.departmentKarabük Üniversitesien_US
dc.description.abstractObjective: The aim of this study was to investigate the effect of royal jelly (RJ), a powerful natural antioxidant, on cyclophosphamide-induced ovarian damage.Methods: Thirty-two Wistar albino rats were divided into four groups. Oral treatment was administered to all rats for 16 days after a single intraperitoneal injection. The control group received intraperitoneal and oral saline; the RJ group received intraperitoneal saline and 100 mg/ kg/day oral RJ; the cyclophosphamide group received intraperitoneal 100 mg/kg cyclophosphamide and oral saline; and the treatment group received intraperitoneal 100 mg/kg cyclophosphamide and 100 mg/kg/day oral RJ. The groups were compared in terms of ovarian reserve tests and histopathological changes in the ovary and uterus.Results: All follicle counts were higher in the treatment group than in the cyclophosphamide group. The increase in the number of preantral follicles (p=0.001) and the decrease in the number of atretic follicles (p=0.004) were statistically significant. RJ treatment significantly improved follicular degeneration and cortical fibrosis in the ovary and epithelial and gland degeneration in the uterus due to cyclophosphamide toxicity.Conclusion: According to these results, RJ reduces cyclophosphamide-related ovarian and endometrial damage in rats. For this reason, it should be further investigated to determine its effects on reproductive function.en_US
dc.identifier.doi10.5653/cerm.2022.05596
dc.identifier.endpage43en_US
dc.identifier.issn2233-8233
dc.identifier.issn2233-8241
dc.identifier.issue1en_US
dc.identifier.pmid36935410en_US
dc.identifier.scopus2-s2.0-85150810349en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage34en_US
dc.identifier.urihttps://doi.org/10.5653/cerm.2022.05596
dc.identifier.urihttps://hdl.handle.net/20.500.14619/7866
dc.identifier.volume50en_US
dc.identifier.wosWOS:000941567700005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKorean Soc Reproductive Medicineen_US
dc.relation.ispartofClinical and Experimental Reproductive Medicine-Cermen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCyclophosphamideen_US
dc.subjectOvarian follicleen_US
dc.subjectOvarian reserveen_US
dc.subjectRoyal jellyen_US
dc.titleIdentification of royal jelly as a potential new drug to protect the ovarian reserve and uterus against cyclophosphamide in ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu